Proper archiving of clinical study documents is an important practice for maintaining the quality, integrity, and usability of study data, and for ensuring regulatory compliance. These aspects are especially important in the context of RWE studies, where the scope and complexity of the regulatory requirements and standards, can differ significantly across and between regions. For example, here are some country-specific archiving timelines for observational drug studies:
Argentina = 2 years
Austria = 15 years
Brazil = 5 years
Germany = 10 years
Japan = 5 years
Netherlands = 15 years
South Korea = 3 years
Turkey = 5 years
According to ISPE GPP, where there are no specified national or regional requirements for retention of study materials, the archive should be maintained for at least five years after final report or first publication of study results, whichever comes later.
Additional considerations when determining what to archive and for how long, include:
[1] Legal Protection (Contractual Obligations): Archiving documents can offer protection in the event of legal questions or disputes related to the conduct of the study, data ownership, patient consent, adverse event reporting, etc. If you are a vendor, check study management contracts for any document retention obligations.
[2] Real-World Study Document Index (RWS-DI): The RWS-DI is a framework developed by a working group of real-world study (RWS) experts to address the challenges of filing essential documents for non-interventional and observational studies. Designed to be consistent with the TMF RM format and structure, but removes artifacts specific to clinical trials and replaces terminology such as “trial” with “study” and “subject” with “patient.”
In conclusion, the process of archiving clinical study documents should not be overlooked, especially in the arena of RWE studies. Regulatory compliance, data validation, legal protection, and future research potential hinge on the effective preservation of these important materials. As the rules can differ wildly from Argentina’s 2-year requirement to Austria and Netherlands’ 15 years, it’s critical to be aware of both regional specifics and overarching guidelines like the ISPE GPP’s five-year rule. Additionally, tools like the RWS-DI provide a specialized framework to ensure that archiving practices are tailored to the unique needs of RWE studies. So, when you’re next managing an observational study, remember – good archiving isn’t just about meeting regulations; it’s about safeguarding the integrity of your study, its results, and the future studies it may inspire.
Share this story...
Real World Evidence (RWE) 101 – HIPAA
RWE 101 - HIPAA HIPAA (Health Insurance Portability and Accountability Act), enacted in 1996, is a federal law in the United States that establishes regulations for the protection of [...]
Real World Evidence (RWE) 101 – The Common Rule
RWE 101 - The Common Rule The Common Rule plays a significant role in the governance of observational studies. The Common Rule refers to a set of regulations and [...]
Real World Evidence (RWE) 101 – The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule)
RWE 101 - The Tuskegee Syphilis Study (the reason we have the Belmont Report and the Common Rule) The Tuskegee Syphilis Study, conducted from 1932 to 1972, stands as [...]
Real World Evidence (RWE) 101 – Observational Study vs Non-Interventional Study
RWE 101 - Observational Study vs Non-Interventional Study In the context of real-world evidence (RWE), the terms "observational study" and "non-interventional study" are often used interchangeably to refer to [...]
Real World Evidence (RWE) 101 – Are Non-Interventional Studies Regulated?
RWE 101 - Are Non-Interventional Studies Regulated? Yes, non-interventional studies (NIS) are regulated. While the specific regulations and requirements may vary by country, there are generally guidelines and provisions [...]
Real World Evidence (RWE) 101 – Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS)
RWE 101 - Postmarket Requirements (PMR) vs Post-Authorisation Safety Studies (PASS) In the context of real-world evidence (RWE) and regulatory frameworks, postmarket requirements (PMRs) and post-authorization safety studies (PASS) [...]







